One of the areas of progress in modern medicine has been in producing cures in relatively large numbers of children with disseminated malignant disease. Intensive anticancer therapy, however, generates a host of new problems and often places enormous burdens on the sick child and the child’s family. Fundamental to the treatment of malignant disease in childhood today are not only the drugs that are needed to suppress the growth of neoplastic cells, but also the care which is necessary to prevent mortality and to minimize unpleasant effects of the disease and treatment.
KeywordsVenous Access Platelet Transfusion Morphine Sulphate Acute Lymphocytic Leukaemia Granulocyte Transfusion
Unable to display preview. Download preview PDF.
- 3.Deisseroth AB, Abrams R, Holohan T, Bode U, Fontana J, Colbert D, Wright D (1982) Blood component replacement, applications of the continuous flow centrifuge, and bone marrow transplantation. In: Levine AS (ed) Cancer in the young. Masson, New York, pp 285–298Google Scholar
- 4.Schneider W, Schnaidt M, Wernet D, Sugg U, Schunter R, Dopfer R, Schuder J, Trenner J, Niethammer D (1984) Reasoning, clinical aspects, and results of a guarded platelet substitution therapy in children with acute lymphoblastic and myeloblasts leukemia treated according to the BFM therapy studies. Eur Paediatr Haematol Oncol 1: 47–50CrossRefGoogle Scholar
- 6.Jaffe N, Buell DN (1979) Supportive care: twenty years of progress. In: Pochedly C (ed) Pediatric cancer therapy. Pitman Medical, New York, pp 261–274Google Scholar
- 17.Futterman E, Hoffman I (1973) Crisis and adaptation in the families of the fatally ill children. In: Anthony J, Koupernick C (eds) The child in his family. The impact of disease and illness, vol 2. Wiley, New York, pp 127–143Google Scholar